Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Clinical trial NCT03729609 · COMPLETED
Trial details
- NCT number
- NCT03729609
- Sponsor
- Takeda
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2018-11-01
- Primary completion
- 2023-09-27
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.